APELLIS PHARMACEUTICALS INC's ticker is and the CUSIP is 03753UAB2. A total of 17 filers reported holding APELLIS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,863,606 | -47.3% | 11,766,000 | 0.0% | 0.17% | -50.1% |
| Q2 2023 | $28,207,024 | +24.4% | 11,766,000 | -3.4% | 0.34% | +25.0% |
| Q1 2023 | $22,669,901 | +21.2% | 12,175,000 | 0.0% | 0.27% | +38.1% |
| Q4 2022 | $18,702,513 | +15.0% | 12,175,000 | +46.2% | 0.19% | +10.9% |
| Q3 2022 | $16,256,000 | -75.0% | 8,325,000 | -81.0% | 0.18% | -73.1% |
| Q2 2022 | $65,016,000 | -33.0% | 43,874,000 | -28.5% | 0.65% | -31.3% |
| Q1 2022 | $97,046,000 | +36.9% | 61,374,000 | +30.9% | 0.95% | +43.5% |
| Q4 2021 | $70,903,000 | +69.3% | 46,874,000 | +37.9% | 0.66% | +82.8% |
| Q3 2021 | $41,869,000 | -47.5% | 33,996,000 | -20.7% | 0.36% | -40.5% |
| Q2 2021 | $79,763,000 | +1796.4% | 42,855,000 | +1328.5% | 0.61% | +1586.1% |
| Q1 2021 | $4,206,000 | -80.0% | 3,000,000 | -76.0% | 0.04% | -76.6% |
| Q4 2020 | $20,991,000 | +54.4% | 12,502,000 | 0.0% | 0.15% | +27.3% |
| Q3 2020 | $13,594,000 | – | 12,502,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DeepCurrents Investment Group LLC | 15,000,000 | $35,954,355 | 1.42% |
| WOLVERINE ASSET MANAGEMENT LLC | 11,766,000 | $28,207,024 | 0.34% |
| LINDEN ADVISORS LP | 10,000,000 | $23,952,985 | 0.25% |
| Verition Fund Management LLC | 4,796 | $11,487,633 | 0.15% |
| LORD, ABBETT & CO. LLC | 11,712,000 | $28,044 | 0.10% |
| PALISADE CAPITAL MANAGEMENT, LP | 1,267,000 | $3,044,070 | 0.08% |
| LAZARD ASSET MANAGEMENT LLC | 14,242,000 | $34,113 | 0.04% |
| KORNITZER CAPITAL MANAGEMENT INC /KS | 300,000 | $717,076 | 0.01% |
| D. E. Shaw & Co., Inc. | 5,000,000 | $11,995,383 | 0.01% |
| Citadel Advisors | 11,500,000 | $27,556,934 | 0.01% |